Center of excellence for myeloma care, PCOS Awareness Month and CLR 131 in pediatric cancers
September 23, 2021

Goals and challenges of developing a patient focused myeloma center of excellence

with  Dr. Carl Ola Landgren
Sep 8, 2021, 3:15 PM EST

The multiple myeloma treatment field has undergone several changes over the past 10-20 years. The average overall survival has changed from 1-3 years to 10-20 years. Yet, there is no established curative therapy for multiple myeloma. However, advanced monitoring with minimal residual disease (MRD) testing, targeted imaging, and cutting-edge molecular profiling of residual disease post-therapy will drive the field forward in the coming few years. With better identification of residual disease as well as detection of early recurrences, patients can look forward to improved remission-free follow-ups. Multiple myeloma survivor and advocate, Gary Petersen talks to world renowned multiple myeloma specialist Dr. Carl Ola Landgren as part of the CureTalks with Gary series. Gary discusses the goals and challenges of developing a best of class patient-focused myeloma center of excellence with Dr. Landgren. Hematologic oncologist Ola Landgren, MD, PhD, was recently appointed the inaugural leader of a new research program, Experimental Therapeutics, at Sylvester Comprehensive Cancer Center at the University of Miami Health System and the Miller School of Medicine. Dr. Landgren, who was Chief of Myeloma Service for the past 6 years at Memorial Sloan Kettering Cancer Center, will also serve as Chief of the Myeloma Program at Sylvester.  


Dr. Carl Ola Landgren
Gary Petersen
Sep 1, 2021, 4:00 pm EST
Polycystic ovary syndrome (PCOS) is a chronic disorder affecting 1 in 10 women of reproductive age. It is the primary cause of reduced frequency of ovulation and anovulation at the reproductive age and is commonly associated with infertility. The prevalence of infertility in women with PCOS varies between 70-80%. Can early PCOS diagnosis prevent related infertility? How can the wait period before family building be reduced? What are the treatment options for women dealing with PCOS related infertility? On world pcos day we talked to board certified reproductive endocrinologist Dr. Ilana Ressler of RMACT, who answered these and more related questions from the PCOS community. Dr Ressler educated us about the prevention, diagnosis, treatment and management of infertility occurring as a result of PCOS that went undiagnosed or was diagnosed late.

Dr. Ilana Ressler 
Lisa Rosenthal
Tatiana Alafouzo
Dr. Ami Patel
Shweta Mishra
July 12, 2021, 1:00 pm EST
Many pediatric cancers have very poor overall survival rates once they relapse or if they do not respond to initial standard treatments. Radiotherapy plays an important role in the treatment of these cancers. However, if the cancer has metastasized to many sites, external beam radiotherapy becomes impracticable and too harmful to healthy body tissues. CLR 131 by Cellectar Biosciences, is a radio iodinated therapeutic that selectively delivers radiation to malignant tumor cells, thus minimizing radiation exposure to normal tissues. It consists of a cancer-targeted small-molecule compound radiolabeled with isotope iodine-131. CLR 131 has demonstrated tumor selective uptake and therapeutic efficacy in various pediatric cancers. We talked to Dr. Mario Otto, University of Wisconsin School of Medicine and Public Health and Dr. Daniel Morgenstern, SickKids about use of CLR 131 in pediatric cancers, status on the clinical trials and scope of targeted radiotherapeutics in pediatric cancers.

Dr. Mario Otto
Dr. Daniel Morgenstern
Jeremy Pivor
Mark Unger
Shweta Mishra
Subscribe to CureTalks YouTube channel here.
Our Picks
TrialX Editor